Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Sir G et al. | Antagonistic Effect of Oxytocin and Tacrolimus Combination on Adipose Tissue - Derived Mesenchymal Stem Cells: Antagonistic effect of oxytocin and tacrolimus. | 2018 | Biomed. Pharmacother. | pmid:29136956 |
Kirchhof J et al. | Learned immunosuppressive placebo responses in renal transplant patients. | 2018 | Proc. Natl. Acad. Sci. U.S.A. | pmid:29610294 |
Felipe C et al. | Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients. | 2018 | Ther Drug Monit | pmid:29271815 |
Kimura Y et al. | Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. | 2018 | Arch. Toxicol. | pmid:29594315 |
Loeschenberger B et al. | Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells. | 2018 | Eur. J. Immunol. | pmid:29143318 |
Özçakar ZB et al. | Transplantation within the era of anti-IL-1 therapy: case series of five patients with familial Mediterranean fever-related amyloidosis. | 2018 | Transpl. Int. | pmid:29957882 |
Chao YH et al. | Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome. | 2018 | PLoS ONE | pmid:29894515 |
Tang JT et al. | A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. | 2018 | Ann. Transplant. | pmid:29735966 |
Zhang Y and Zhang R | Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. | 2018 | Drug Test Anal | pmid:28851030 |
Choi CB et al. | Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. | 2018 | Lupus | pmid:29448881 |